Evaluation of the Therapeutic Effect of Platelet Rich Plasma (PRP) in Periorbital Hyperpigmentation(POH)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
•Both sexes will be included.
Patient with Fitzpatrick skin types III-IV
• Patients with known platelet dysfunction syndrome, critical thrombocytopenia (<50,000/ul), any hemodynamic instability.
Patients with chronic medical illness (e.g. diabetes, chronic infections, and blood dyscrasias).
Patients with local inflammatory skin disorders or active herpes infection at the site of the procedure.
Patients on consistent use of anti-coagulants or non-steroidal anti-inflammatory drugs (NSAID) within 48 hours of procedure.
Haemoglobin level< 10 g/dl were also excluded.
Patients with cancer- especially hematopoietic or of bone.
Patients with corticosteroids injection at treatment site within 1 month or systemic use of corticosteroids within 2 weeks.